Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene TherapeuticsAllogene Therapeutics(US:ALLO) Seeking Alpha·2026-04-14 01:41

公司近期业务动态 - Allogene Therapeutics 举行了业务更新电话会议 [1] 公司管理层 - Christine Cassiano 担任首席企业事务与品牌战略官 负责主持电话会议 [1]

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript - Reportify